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Abstract  1 
Recombinant glucarpidase (formerly: Carboxypeptidase G2, CPG2) is used in Antibody Directed Enzyme 2 
Prodrug Therapy (ADEPT) for the treatment of cancer. In common with many protein therapeutics, 3 
glucarpidase has a relatively short half-life in serum and, due to the need for the repeated cycles of the 4 
ADEPT, its bioavailability may be further diminished by neutralizing antibodies produced by patients. 5 
PEGylation and fusion with human serum albumin (HSA) are two approaches that are commonly 6 
employed to increase the residency time of protein therapeutics in blood, and also to increase the half-7 
lives of the proteins in vivo. To address this stability and the immunogenicity problems, ‘biobetter’ 8 
glucarpidase variants, mono-PEGylated glucarpidase, and HSA fused glucarpidase by genetic fusion with 9 
albumin, were produced.  Biochemical and bioactivity analyses, including anti-proliferation, bioassays, 10 
circular dichroism, and in vitro stability using human blood serum and immunoassays, demonstrated that 11 
the functional activities of the designed glucarpidase conjugates were maintained. The immunotoxicity 12 
studies indicated that the PEGylated glucarpidase did not significantly induce T-cell proliferation, 13 
suggesting that glucarpidase epitopes were masked by the PEG moiety. However, free glucarpidase and 14 
HSA-glucarpidase significantly increased T-cell proliferation compared with the negative control. In the 15 
latter case, this might be due to the type of expression system used or due to trace impurities associated 16 
with the highly purified (99.99%) recombinant HSA-glucarpidase. Both PEGylated glucarpidase and 17 
HAS-glucarpidase exhibit more stability in human serum and were more resistant to key human proteases 18 
relative to native glucarpidase. To our knowledge, this study is the first to report stable and less 19 
immunogenic glucarpidase variants produced by PEGylation and fusion with HSA. The results suggest 20 
that they may have better efficacy in drug detoxification and ADEPT, thereby improving this cancer 21 
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Introduction  34 
The US Food and Drug Administration has approved more than 180 therapeutic peptides and proteins for 35 
many applications and disease treatments. Because most of these proteins and peptides are smaller in size 36 
than the kidney filtration cutoff of ~70 kDa, they do not have optimal pharmacokinetics. Thus, these 37 
protein and peptide therapeutics have short half-lives in vivo, due to the action of proteases and the 38 
generation of antibodies against them 
1
.  39 
Due to these features, therapeutic proteins and peptides needed to be injected frequently and in high dose. 40 
This not only results in the need for more frequent treatments, often leading to patient non-compliance, 41 
but it also results in reduced drug efficacy.   42 
One of the therapeutic proteins used in cancer therapy is glucarpidase, also known as Carboxypeptidase 43 
G2, CPG2, which originates from the bacterium Variovorax paradoxus (old name, Pseudomonas sp. 44 
strain RS-16). It has no mammalian equivalent 
2, 3
 and is a zinc-dependent dimeric protein with two 45 
subunits of 41 kDa 
4, 5
. Glucarpidase has a relatively restricted specificity and hydrolyzes the C-terminal 46 
glutamic acid residue of folic acid and folate analogues such as methotrexate 
6
. The mechanism of action 47 
of glucarpidase is, therefore, to lower systemic methotrexate levels by rapidly causing methotrexate to be 48 
converted to glutamate and 4-deoxy-4-amino-N 10-methylpteroic acid (DAMPA), both of which undergo 49 
hepatic metabolism.  50 
Glucarpidase, consequently, provides an alternative route for methotrexate elimination in patients with 51 
impaired renal function. This action of glucarpidase on methotrexate makes the enzyme not only a 52 
powerful rescue agent in patients receiving high doses of methotrexate but also helps to avoid life-53 
threatening toxicity in patients with methotrexate intoxications.  54 
The enzyme can also be used in a targeted cancer therapy technique known as Antibody Directed Enzyme 55 
Prodrug Therapy (ADEPT), which has already been implemented for cancer treatment 
7
. 56 
ADEPT consists of two steps (fig. 1), which result in the production of a powerful cytotoxic drug only in 57 
the vicinity of the tumor. In the first step, a tumor-selective antibody is chemically linked to an enzyme 58 
and then administered intravenously to the patient. The second step includes the injection of a non-toxic 59 
drug precursor (Prodrug). 60 
The enzyme, which accumulates at the tumor site via the tumor-specific antibody, converts the prodrug 61 
into an active drug. This therapy, therefore, produces a powerful cytotoxic drug in the vicinity of the 62 
tumor with little toxicity elsewhere in the patient body. One of the enzymes that has been used in the 63 
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ADEPT is the glucarpidase from V. paradoxus strain RS-16, which when applied has been shown to 64 
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Fig. 1.  The principle of ADEPT. The first step is the injection of the antibody-enzyme fusion protein, which 68 
localizes to tumors. The second step is the injection of a prodrug, following clearance of the fusion protein from the 69 
blood. The localized glucarpidase converts the prodrug into the cytotoxic drug, which can diffuse through the tumor 70 
and kill antigen-containing tumor cells as well as tumor cells that are nearby but do not express the relevant antigen, 71 
thus giving a "bystander" effect 
12
.  72 
 73 
The use of glucarpidase in the ADEPT and the drug detoxification are effective but have limitations. The 74 
treatment requires repeated cycles, which results in a severe immune response against the glucarpidase 75 
and, additionally, proteases present in patients’ blood degrade the enzyme thereby limiting its therapeutic 76 
applicability.  77 
We recently isolated a new glucarpidase that shares 94% amino acid identity with the one produced by V. 78 
paradoxus strain RS-16 
13
. We also demonstrated that antibodies raised against the newly isolated 79 
glucarpidase do not react with the one from V. paradoxus strain RS-16.  80 
In this work, we report the production of long-acting variants of our glucarpidase to overcome the 81 
complications related to the multiple cycles of ADEPT. A number of strategies have been developed to 82 
address the issue of immunogenicity and to improve the pharmacokinetics of protein and peptide 83 
therapeutics. These include PEGylation, i.e. the attachment of polyethylene glycol (PEG) polymer chains, 84 
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fusion with human serum albumin (HSA), fusion with non-structured polypeptides, and fusion with the 85 
constant fragment (Fc) domain of a human immunoglobulin (Ig)G 
14
. In this study, we focused our work 86 
on the production of ‘biobetter’ glucarpidases by using PEGylation (PEG) and fusion with the Human 87 
serum albumin (HSA).  88 
PEGylation technology has already been used successfully to produce long-acting proteins. For example, 89 
PEGylated forms of interferon α2b and interferon α2a, which are known commercially as Pegintron and 90 
Pegasys respectively, have been used for the treatment of treatment of patients with melanoma and 91 
hepatitis B. Similarly, a PEGylated version of granulocyte colony-stimulating factor has been used for the 92 
treatment of chemotherapy-induced neutropenia 
15-17
.  93 
Human serum albumin, which has a circulation half-life of nineteen days
18
, has also been used to extend 94 
the half-life of biopharmaceuticals and to maintain their bioactivity
19, 20
. Protein therapeutics that have 95 








In this study, we implemented the two strategies, PEGylation of Lys residues and genetic fusion with 98 
human serum albumin, to produce long-acting glucarpidases to overcome current problems with ADEPT 99 
in cancer treatment.  100 
Glucarpidase is clinically important enzyme in the antibody directed enzyme prodrug therapy and also in 101 
drug detoxification. Both applications have several pitfalls. We report, for first time, the production of 102 
novel glucarpidase variants with long acting and higher stability features than the free enzyme. Our work 103 
will pave the way for clinical investigation and in vivo studies.   104 
 105 
Experimental Section 106 
Bacterial strains, plasmids, and growth conditions.  107 
The following strains of E. coli: Mach1™ T1R cells,  DH5α™ E. coli, both from Thermo Fischer 108 
Scientific were used as cloning hosts and for plasmid propagation. Other strains such as BL21(DE3) RIL, 109 
Bl21 (DE3) and Rosetta™(DE3) Competent Cells (Novagen) were used for protein expression of the 110 
recombinant proteins. The plasmid pEX-K4 (Eurofins) was used for subcloning of the CPG2 to be 111 
conjugated with HSA, and pET28a (Novagen, Stratagen) was used for recombinant protein expression in 112 
E. coli. All recombinant bacterial strains were grown in Luria Bertani broth (Sigma life sciences) for 113 
liquid culture, which was solidified with agar (Sigma life sciences) for solid culture media. 114 
Restriction enzymes, Antibodies and other chemicals 115 
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Restriction endonucleases and other enzymes required for cloning were from New England Biolabs. 116 
NdeI/HindIII were used for subcloning of CPG2 into pEX-K4-HSA, and KpnI/ EcoR1 and HindIII were 117 
used to release the new conjugate into pET28a for expression study, and Calf Intestinal Alkaline 118 
phosphatase was used for vector dephosphorylation. T4 DNA ligase (Thermo Fischer Scientific) was used 119 
for the ligation step. T7 promoter: 5´-TAATACGACTCACTATAGGG-3´ and T7 terminator 5´-120 
GCTAGTTATTGCTCAGCGG-3´ primers were obtained from Eurofins and used as universal primers 121 
for sequencing and subcloning confirmation. For protein purification by nickel affinity chromatography, 122 
Ni-NTA resin (Sigma) was used. Quick-Load® Purple 1 kb DNA Ladder (NEB) was used as the DNA 123 
marker while the SeeBlue Plus2 Prestained ladder (198-10 kDa) (Thermo Fischer Scientific) was used as 124 
protein markers. The GeneJET Plasmid Miniprep and Gel Extraction Kits (Thermo Fischer Scientific) 125 
were used for plasmid mini preparations and for DNA extraction and purification from gels, respectively. 126 
NuPAGE 10% Bis-Tris Gel Novex (Life Technologies) was used for SDS-PAGE Nitrocellulose 127 
Membrane (Thermo Fischer Scientific) was used for immunoblotting. Dialysis tube (Spectra/Por 7 128 
Dialysis Tubing, 10 kDa MWCO, 24 mm Flat-width, 5 meters/roll (16 ft) (Spectrum) and dialysis tube of 129 
50 kDa MWCO (Fischer Scientific) were used for exchanging buffers for proteins. The PEGylation 130 
reagent used was Y-shape (MPEG20K) 2-Succinimidyl Carboxymethyl Ester, MW 40000 (JenKem 131 
Technology). The following antibodies were used: mouse 6x-His Tag Monoclonal Antibody (HIS.H8) 132 
(Invitrogen) (1:2000 dilution), rabbit polyclonal anti Xen-CPG2 antibody (GE Healthcare) (1:2000 133 
dilution), mouse anti-human serum albumin antibody [15C7] (ab10241) (Abcam) (1:500 dilution), rabbit 134 
anti-polyethylene glycol antibody [PEG-B-47] (ab51257) Abcam (1:2000 dilution) were used as primary 135 
antibodies for protein detection and goat anti-Mouse IgG H&L (HRP) (ab205719) from Abcam (1:4000 136 
dilution) and goat anti-Rabbit IgG H&L (HRP) (ab6721) from Abcam (1:5000 dilution) were used as 137 
secondary conjugated antibodies. An ECL chemiluminescent detection reagent (GE Healthcare) was used 138 
as the substrate for detection of bound antibodies in western blotting. 139 
Designing and construction Human Serum Albumin (HSA) to Xen-CPG2  140 
The Human Serum Albumin (HSA) gene was custom synthesized by Eurofins genomics and inserted into 141 
the vector pEX-K4. The resulting construct was transformed into competent E. coli DH5alpha for 142 
propagation. pEX-K4-HSA was digested using NdeI/ HindIII and used as the receiving vector for 143 
insertion of a similarly digested DNA fragment carrying Xen-CPG2, which originated from a pET28a 144 
vector. Plasmid DNA from the resulting construct, designated pEX-K4-HSA-CPG2 and carrying a gene 145 
coding for an HSA-CPG fusion, was digested with KpnI/HindIII to release the HSA-CPG2 gene fusion 146 
and then further digested with EcoRI prior to insertion into the EcoRI/HindIII digested expression vector 147 
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pET28a. The structure of the resulting construct, pET28a-Xen CPG2-HSA, was checked by restriction 148 
digestion and sequencing using T7 promoter and terminator universal primers. 149 
 150 
Protein Expression of HSA Xen-CPG2 protein  151 
E. coli BL21(DE3)RIL cells containing the pET28a-Xen CPG2-HSA were grown in LB medium 152 
supplemented with kanamycin and chloramphenicol at final concentrations of 33 µg/mL and 34 µg/mL, 153 
respectively. Following overnight incubation at 37 ᵒC with shaking (200 rpm), 5 ml of the culture was 154 
added to 1L of fresh LB-broth containing the required antibiotics. The culture was incubated at 37 ᵒC for 155 
4 hours in an incubator shaker until the optical density at 600 nm was 0.5-0.6, at which point the culture 156 
was induced using isopropyl-β-D-thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM or left 157 
uninduced as the control. Following further incubation for four hours at 37 ᵒC at 200 rpm, cells were 158 
harvested by centrifugation for 15 min at 4 ᵒC and 4000 rpm. Cell pellets were re-suspended in 20 mM 159 
Tris buffer, pH 8 and 50 mM NaCl and were disrupted by sonication (MSE Soniprep 150 Plus) on ice (8 160 
cycles of 30 sec pulses followed by 30 sec rest). Cell lysates were centrifuged at 14,000 rpm for 30 min at 161 
4 ᵒC for separation of the soluble and insoluble fractions. Each fraction was mixed with an equal volume 162 
of 2X sample buffer, denatured by boiling for 10 minutes at 95 °C, and then analyzed by SDS-PAGE. For 163 
maximum soluble protein production, cultures were induced with IPTG overnight at 20 °C.  164 
Ni-NTA Purification of the HSA Xen-CPG2  165 
The Xen-HSA CPG2 fusion protein was designed with a six-histidine tag at its N-terminus. 166 
Consequently, this protein was purified by Ni-NTA affinity chromatography. The resin was washed with 167 
sterile Milli-Q water and activated using a binding-washing buffer containing Tris (20 mM) pH 8, NaCl 168 
(50 mM), BME (5 mM), and imidazole (20 mM). Total soluble protein from E. coli BL21(DE3)RIL cells 169 
containing the pET28a-Xen CPG2-HSA was incubated with the resin with gentle agitation for 30 min at 4 170 
°C. The combined resin was separated by gravity, the flow-through collected, and then the resin was 171 
washed repeatedly with wash buffer. The target protein bound to the resin was released by adding ice-172 
cold elution Tris buffer containing 400 mM imidazole. The eluted protein was dialyzed against 100 mM 173 
Tris-HCl pH 7.3 containing 0.2 mM ZnSO4 for activity assay. All collected fractions of protein 174 





Conjugation of Poly Ethylene Glycol (PEG) into Xen-CPG2  178 
The purified CPG2, at a concentration of 0.5mg/ml,  was dialyzed against 1X PBS pH 6 and subjected  179 
PEGylation by addition 1–5 fold molar excess of PEGylation reagent Y-shape (MPEG20K)2 180 
Succinimidyl Carboxymethyl (SCM) Ester of MW 40,000 (JenKem Technology) in 100 mM sodium 181 
phosphate at pH 6, at room temperature for 30 min – 4 h. The same reaction was carried out at 30 ᵒC, The 182 
PEGylation reaction was followed by SDS Gel analysis and the incubation time was prolonged to 183 
optimize the PEG binding to the CPG2 protein using a modification of the previous method
25
. 184 
. Larger scale PEGylation was achieved by mixing of 5 mg/ml of the CPG2 protein with a 3-fold molar 185 
excess of PEGylation reagent Y-shape (Y-SCM-40K), with rapid and thorough shaking by vortex 186 
followed by incubation at 30 ᵒC in an incubator shaker at 200 rpm for 10 hours. The PEGylated CPG2 187 
mixture was then subjected to Ni-NTA purification to remove the excess non-reactive PEGylation reagent 188 
and further purified by gel filtration using an AKTA purifier. Finally, the purified PEGylated CPG2 189 
conjugate was isolated and quantified. 190 
 Determination of PEGylated and HSA conjugated CPG2 catalytic enzyme kinetics 191 
The glucarpidase activities of the pure recombinant HSA-CPG2 (≈2 μg/ml) and PEG-CPG2 (≈2 μg/ml) 192 
was determined by measuring methotrexate hydrolytic activity using Tris buffer (0.1 M Tris-HCl pH 7.3 193 
and 0.2 mM ZnSO4) containing Methotrexate (MTX) (0.27 mM) as substrate and measured 194 
spectrophotometrically using Plate Reader Infinite M200 PRO NanoQuant (TECAN) at 320 nm, 37 ᵒC for 195 
1 hour. 196 
Kinetic studies of these modified CPG2 (HSA Xen-CPG2 and PEG Xen-CPG2 of ≈2 μg/ml), were also 197 
assayed by testing their activities at different MTX concentrations (30-420 µM) in the required Tris-198 
ZnSO4 buffer using Nunc 96 plates with UV transparent flat bottom wells, to determine the stability 199 
constant (Km) and the rate of reaction (Vmax). All reactions were carried out at 37 °C for 2 min and the 200 
decrease in absorbance at 320 nm was monitored using Plate reader, Infinite M200 PRO NanoQuant. The 201 
Michaelis-Menten equation was used for determination of the actual values of Km, Kcat, and Vmax of 202 
each protein using GraphPad PRISM 6 software. 203 
One unit of the enzyme represents the amount of enzyme in mg required for hydrolysis of 1 mM of MTX 204 
per min at 37 ᵒC. The enzyme activity per ml of protein was calculated using 8,300 as the molar 205 





Circular Dichroism and secondary structure analyses of the modified CPG2  209 
a. Pre-CD Scanning 210 
Purified preparations of the CPG2 (HSA Xen-CPG2 and PEG Xen-CPG2) proteins were dialyzed against 211 
Milli-Q water 4 times each for 18 hours, followed by centrifugation for 30 min. at 4 °C. A NanoDrop 212 
2000 spectrophotometer (Thermo Scientific) was used for measuring the protein concentration and the 213 
required concentration for CD measurement for each protein was adjusted to about 8-10 µM. The 214 
extinction coefficients were taken as ε = 66305 and 23380 M-1 cm-1 for HSA Xen-CPG2 and PEG Xen-215 
CPG2, respectively.  216 
b. Circular dichroism (CD) 217 
Measurements were made using Chirascan™ Plus CD Spectrometer (Applied Photophysics). CD 218 
scanning of the modified CPG2 in far UV spectral region was measured using a SUPRASIL Quartz 219 
cuvette demountable rectangular (Hellma®) of 0.2 mm light-path length (sample volume ∼70 μl). Scans 220 
were made from 260 to 180 nm. All proteins were tested at conc. 8-10 µM at 20 °C. The applied CD 221 
parameters were as follows: bandwidth 1 nm and scan time per point of 0.5 sec. Four scans were taken 222 
per one sample, and these readings were averaged and smoothed using the CD analysis software. The 223 
produced spectra were subtracted from an averaged CD spectra of the used blank (Milli Q water) 224 
baseline.       225 
c. CD- deconvolution method 226 
Protein secondary structure of the pure recombinant modified CPG2 were calculated by CD data 227 
deconvolution analysis using the CDNN (version 2.1) software tool. The Deconvolution calculation was 228 
carried out in the spectral range of (180–260 nm). The parameters used in the deconvolution calculations, 229 
the number of residues and molecular weight were taken as 1018 AAs, with 112.38344 kDa for HSA 230 
Xen-CPG2 and 81.76148 kDa and 392 AAs for PEG Xen-CPG2 respectively, and 0.02 cm light-231 
pathlength of the cuvette was used. 232 
Mass Spectra analysis of HSA-glucarpidase fusion protein  233 
The purified fusion protein was analyzed on 8% SDS-PAGE electrophoresis. The extracted 234 
band-containing HSA-glucarpidase protein was subjected to protein digestion with Trypsin Gold 235 
(mass spec grade, Promega) using in gel digestion protocol according to manufacturer’s 236 
instruction.  237 
The digested proteins were then analyzed by tandem mass spectrometry (LC-MS/MS) using 238 
LC/MS LTQ-Orbitrap Elite. 239 
10 
 
Extracted data was analyzed to identify the protein sequence against protein database using 240 
PEAKS Studio software. 241 
CPG2 and its modified forms stability assay  242 
The structural stability of resulting purified proteins was determined by incubation of the 0.1µg/µl 243 
purified free Xen-CPG2, PEG Xen-CPG2 and HSA Xen-CPG2 with human serum samples from a normal 244 
donor at 37 ᵒC. Samples collected every 5 days for 15 days and analyzed by western blotting. Samples 245 
(1µg/lane) were separated on non-denatured gels (native-PAGE) and transferred to nitrocellulose 246 
membranes electrostatically. The resulting membranes were blocked with 5% non-fat milk in 1x PBS for 247 
1 hour at room temperature, then incubated with rabbit anti Xen-CPG2 antibody (1:2000) in 1% non-fat 248 
milk for 1 hour at room temperature. Following washing, the membranes were incubated with a 249 
secondary antibody (horseradish peroxidase conjugated mouse anti-rabbit antibody), the antibody binding 250 
detected with ECL chemiluminescent detection reagent as described by the supplier (GE Healthcare). 251 
A further serum stability assay was carried out to investigate the functional stability of the resulting CPG2 252 
proteins. 0.1µg/µl of purified free CPG2, PEG Xen-CPG2and HSA Xen-CPG2 proteins were incubated 253 
with serum samples from a normal donor at 37
o
C for more than12 days. A sample was taken every 2 days 254 
and the catalytic activity of the glucarpidase moieties was measured using the MTX hydrolysis assay 255 
described above. The percentage of remaining activity at each point was calculated and plotted against the 256 
time of sample taking.  257 
Ex-vivo immunogenicity  258 
The immunogenicity of the resulting purified proteins was investigated using a proliferation assay for 259 
human peripheral blood mononuclear cells (PBMCs) from normal healthy donors. Total blood samples 260 
were collected and the PBMCs separated using ficoll solution (Sigma) and density centrifugation. The 261 
isolated PBMCs were cultured at 1 x 10
6
 cells/ml of X-vivo medium in 96 well plates. Cells were 262 
incubated for 48 hours at 37 °C with the purified endotoxin-free proteins (free Xen-CPG2, PEG Xen-263 
CPG2, and HSA Xen-CPG2) (10µg/ml). Pierce LAL Chromogenic Endotoxin Quantitation Kit was used 264 
to detect the level of endotoxin in the purified CPG2 protein samples and, where necessary, endotoxin 265 
levels were reduced to > 0.1EU/ml using Pierce™ High Capacity Endotoxin Removal Resin. Following 266 
incubation for 48 hours, 10µl of Cell Counting Kit-8 solution (CCK-8) (Sigma) was added to each well 267 
and incubated for 3 hours at 37 °C. The absorbance of resulting color was measured at 450 nm using 268 
Infinite M200 PRO NanoQuant Plate Reader. Endotoxin level of the resulting purified proteins was 269 
lowered to ˂0.1EU/ml using Pierce™ High Capacity Endotoxin Removal Resin, followed my measuring 270 
endotoxin level using Pierce™ LAL Chromogenic Endotoxin Quantitation Kit.  271 
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Statistical analysis 272 
The resulting data are presented as means a ± standard deviation of the means from at least three 273 
independent experiments. Significance was obtained by statistical analysis using student t-test (two-274 
tailed). Graph Pad Prism software was used for all analysis and the significance level was set at ≤0.05. 275 
 276 
Results 277 
Production of CPG2 Modifications 278 
a. HSA fusion protein design, expression, and purification 279 
The Xen-CPG2 gene was fused in-frame to the 3’ end of a gene encoding HSA (Fig 2a) as described in 280 
the Experimental Section. The fusion gene was then sub-cloned into the pET28a expression vector and 281 
transformed into E. coli BL21 (DE3)RIL. Following induction of expression, recombinant HSA Xen-282 
CPG2 protein was purified using Ni-affinity chromatography. SDS-PAGE suggested that the protein was 283 
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Fig 2. Design and purification of the HSA-Xen-CPG2 fusion protein. a) Standard recombinant DNA techniques 303 
were used to create an in-frame fusion between the 5’ end of the Xen-CPG2 gene and the 3’ end of the human HSA 304 
gene. A sequence encoding a linker (YGGGGSGGGGSGGGG) was inserted between the HSA and CPG2 genes. b) 305 
The HSA Xen-CPG2 fusion protein was expressed in E. coli, purified using Ni-NTA affinity chromatography, and 306 
analysed by SDS-PAGE. Lane M showed the SeeBlue Plus2 Pre-stained Protein Standard (198-3 kDa). Lane 1, total 307 
soluble protein; lane 2, flowthrough during Ni-NTA affinity purification; lane 3, proteins released during washing of 308 
Ni-NTA beads; lanes 4-6, eluted fractions. Proteins were visualized by Coomassie blue staining, indicating >90% 309 
purity of the eluted protein. As expected, the fusion protein had an MW of ≈ 112 kDa. 310 
 311 
b. PEGylation technology of Xen-CPG2  312 
To extend the half-life and protein stability of Xen-CPG2, and hence improve ADEPT and cancer 313 
treatment, polyethylene glycol (PEG) chains were tethered to Xen-CPG2 using PEGylation technology, 314 
thereby increasing its hydrodynamic size. PEGylation was achieved by employing a Y-shaped 315 
(MPEG20K)2 succinimidyl carboxymethyl ester of MW 40,000 (JenKem Technology) that reacts with 316 
the amino groups of lysine side chains on the target protein. To reduce the formation of different 317 
PEGylated chain lengths on the protein and to maximize the degree of protein PEGylation, the reaction 318 
condition was first optimized in trials that systematically varied the time of exposure to the PEGylation 319 
reagent. The PEGylated protein was then purified by Ni-affinity chromatography and further purified by 320 















Fig 3. PEGylation of Xen-CPG2 using SCM reagent.  328 
a) SDS-PAGE of Xen-CPG2 at different stages of purification. Xen-CPG 2 was purified as described in the 329 
Materials & Methods section. Lane M1 shows a SeeBlue Plus prestained protein marker (‎3 to 198 kDa) while lane 330 
M2 showed a PageRuler Unstained Protein Ladder (10 kDa to 200 kDa). Lane 1, total soluble protein; lane 2, 331 
flowthrough during Ni-NTA affinity purification; lane 3, proteins released during washing of Ni-NTA beads; lanes 332 
4-7, eluted fractions.  333 
b) SDS-PAGE of Xen-CPG2 at different stages of PEGylation. Panel 1. Lanes 1 and 2, pure non-PEGylated Xen-334 
CPG2 and PEGylated Xen-CPG2, before removal of PEGylation reagent. Panel 2. Lanes 1, and 2, pure non-335 
PEGylated Xen-CPG2 and PEGylated Xen-CPG2, respectively, after removal of PEGylation reagent by affinity 336 
purification. Panel 3. PEGylated Xen-CPG2 and non-PEGylated CPG2 after purification and concentration. Lanes 1 337 





The purity of the resulting purified protein is crucial for further investigations as the presence of any non-339 
modified, native CPG2 might interfere and affect the end result. Thus, the purity of the PEGylated- and 340 
HSA-fused CPG2 was confirmed by western blot analysis (Fig 4). The results indicated that the 341 




Fig 4. Western blot analyses of different forms of CPG2 relative to the wt.  Lane M, SeeBlue Plus2 Prestained 346 
ladder (198-10 kDa), while lanes 1-3 are free Xen-CPG2, PEGylated Xen-CPG2 and HSA-Xen-CPG2, respectively. 347 
Panel a shows SDS-PAGE of the three purified proteins while panels b-e show the results of immunoblots with anti-348 
His-tag antibody, anti-CPG2 antibody, anti-PEG antibody and anti-HSA antibody, respectively. 349 
 350 
PEGylation and HSA-fusion affects the hydrolytic activity of CPG2 351 
E. coli cells expressing the HSA-CPG2 fusion protein were tested for glucarpidase activity by assessing 352 
the degree of folate hydrolysis using agar plates supplemented with folate in the growth medium. 353 
Colonies were dark orange color and were surrounded by clear zones suggesting that fusion with HSA did 354 












Fig 5. Development of folate-specific hydrolytic activity of E. coli expressing recombinant fused HSA-Xen-CPG2 365 
or wild-type Xen-CPG2. Cells were inoculated on LB agar supplemented with folate and IPTG, and the relevant 366 




The catalytic activity of PEGylated- and HSA-fused CPG2 proteins was further investigated by 371 
measuring the rate of MTX hydrolysis by the purified proteins (Fig 6). The derived kinetic parameters for 372 
Xen-CPG2, PEG-Xen-CPG2 and HSA-Xen-CPG2 were, respectively: Vmax values: 24.35 ±1.91, 20.69 373 
±1.428, 48.72 ± 4.389 µM/min; Km values, 50.56 ± 10.71, 69.97 ± 17.12, 66.14 ± 21.85 µM;  and Kcat 374 
values: 11.49 ± 0.1947, 9.759 ± 0.2093, and 8.4 ± 0.2401 S
-1
.











Fig 6. Activity assay of different forms of Xen-CPG2 on hydrolysis of methotrexate (MTX). The activity of free 386 
Xen-CPG2 (blue), the activity of HSA-Xen-CPG2 (black) and activity of PEG-Xen-CPG2 (green) relative to the 387 





PEGylation and HSA conjugation enhance the structural and functional stability of CPG2 390 
To investigate the stability of the PEGylated and HSA-conjugated CPG2 proteins, they were incubated 391 
with serum from healthy donors at 37
o
C. Samples were taken every 2 days and tested for CPG2 392 
enzymatic activity. The resulting remaining percentage activity (Fig 7) indicates that PEGylated and HSA 393 
conjugated CPG2 proteins retained more than 50% of their enzyme activity after 14 days. In contrast, 394 
Xen-CPG2 retained less than 40% of its activity.  395 
 396 
 397 
Fig 7. Remaining catalytic activity of different CPG2 variants following incubation in human serum. The proteins 398 
(0.1 mg/ml) were incubated in serum at 37oC for 14 days and the remaining methotrexate hydrolysis activity was 399 
measured at 48 hour intervals. 400 
 401 
 402 
The results suggest that genetic fusion of CPG2 with HSA was better at stabilizing CPG2 activity in 403 
serum (with ~60% of activity maintained at day 14), compared with the PEGylated form. To further 404 
investigate the structural stability of the proteins, samples were incubated in serum prior to separation by 405 
native PAGE and analysis by immunoblotting using anti-CPG2 antibodies. Free CPG2 was progressively 406 
degraded as the incubation time increased from Day 10 to Day 15 (Fig 8). In contrast, PEGylated and 407 
HSA-conjugated CPG2 remained relatively intact from Day 0 to Day15, indicating that the engineered 408 





Fig 8. Stability of different CPG2 variants in normal human serum. The proteins were incubated in serum and 412 
samples were taken on days 0, 10 and 15. The samples were separated by native PAGE and analyzed by western 413 
blotting using anti Xen-CPG2 antibody. Lane M, SeeBlue Plus2 Prestained ladder (198-10 kDa); lanes 1, 2, and 3 , 414 
samples taken on days 0, 10, and 15, respectively. Panel a: serum only as control; panel b: Xen-CPG2; panel c: 415 
PEG-Xen-CPG2; and panel d: HSA-Xen-CPG2.  416 
 417 
Circular dichroism spectral analysis 418 
Circular dichroism (CD) spectroscopy was used to obtain information on how PEGylation or fusion with 419 
HSA might affect the overall structure of CPG2 (Fig 9). CD is based on the principle that the differential 420 
absorption of polarized light by a chiral molecule (i.e. right- and left-handed rotation of circularly 421 
polarized light induced by optically active molecules in the sample) provides structural information. The 422 















Table 1 - Comparison of secondary structures of Xen-CPG2, PEG-CPG2, and HSA-CPG2 435 







Alpha helix  69.3 81.7 30.9 
Anti-parallel  1.2 0.6 11.1 
Parallel  3.2 1.6 8.9 
Beta-turn  11.3 9.1 17.4 
Random coil 14.9 6.7 31.5 
Total Sum  99.9 99.7 99.8 
 436 
1
 The relative amounts of different secondary structures in Xen-CPG2, PEG-CPG2, and HSA-CPG2 were calculated 437 
from the spectral data shown in Fig 8 by CDNN deconvolution analysis. The average values of each secondary 438 
structure component following four sets of measurements is shown as percentages.   439 
 440 
The percent composition of the four main secondary structure components calculated by CDNN 441 
deconvolution analysis of the obtained spectra (Fig 9.), consists of 69.3% alpha helix, 1.2% antiparallel, 442 
3.2% parallel, 11.3% beta turn, and 14.9% random coil for Xen-CPG2 
24
 . In contrast, and 81.7% helix, 443 
0.6% antiparallel, 1.6% parallel, 9.1% beta turn, and 6.7% random coil for PEG-CPG2 and 30.9% 444 

















Fig 9. Far UV spectroscopy of free Xen-CPG2, PEG-Xen-CPG2, and HSA-Xen-CPG2 using CHIRASCAN. The 460 
lines labeled Smooth 0, 1, and 2 represent the CD spectra for Xen-CPG2, PEG Xen-CPG2, and HSA Xen-CPG2, 461 
respectively  462 
 463 
 464 
In vitro immunogenicity of PEGylated and HSA conjugated CPG2 proteins 465 
The immunogenicity of the produced proteins was examined using PBMCs from healthy donors. The 466 
proliferation of the cells was detected following incubation with either the vehicle (negative control), LPS 467 
(positive control) or the endotoxin low produced proteins (CPG2, PEGylated, and HSA conjugated Xen-468 
CPG2). As shown in Fig 10. PEG-Xen-CPG2 was significantly low in immunogenicity compared to the 469 
positive control. Fusion with HSA also lowered CPG2 immunogenicity significantly in most of the 470 





Fig 10. Human PBMC proliferation assay (Immunogenicity). PBMC from healthy donors incubated with purified 476 
proteins followed by determining their proliferation. A significant increase was found in the positive control, 477 
Lipopolysaccharide (LPS) compared with all control groups with the vehicle only. When comparing with negative 478 
control, PEG Xen-CPG2 treated cells in all groups showed no significant increase in proliferation, whereas HSA 479 
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Xen-CPG2 treated cells showed similar result except in two donors. ** P ˂ 0.01, *** P ˂ 0.0001, an unpaired test 480 
was used to analyze data. P ˂ 0.05 was considered statistically significant. 481 
Discussion  482 
Antibody directed enzyme prodrug therapy (ADEPT) is an effective strategy for targeted cancer 483 
treatment. The technique, however, suffers from two significant drawbacks; namely, the patient immune 484 
system will progressively generate antibodies against the enzyme due to the repeated injection of CPG2, 485 
thereby limiting its efficacy, and the enzyme will be liable to degradation by the patient’s proteases.  486 
In our previous work 
13
 we isolated a novel glucarpidase whose raised antibodies did not cross-react with 487 
the one in clinical use. In principle, therefore, it would be possible to delay the production of antibodies in 488 
a patient by alternating the use of the two versions of CPG2. However, this strategy may not totally solve 489 
the problem and in any case does not address the issue of limited protein stability in a patient’s blood, e.g. 490 
due to proteolytic degradation 
26
. In this study, therefore, we adopted a different approach to produce 491 
biobetter glucarpidases, which should both reduce the potential for antibodies production and also protect 492 
the protein against endogenous proteases.   493 
PEGylation of proteins and other biomolecules is one of the most effective strategies to produce biobetter 494 
therapeutics. It improves the pharmacokinetics and pharmacodynamics of the conjugated molecules in 495 
relation to the non-conjugated one, increases water solubility and also protects against proteolytic 496 
degradation. On the other hand, human serum albumin has a long half-life in the body and proteins fused 497 
to this protein also have extended half-lives 
27, 28
. 498 
Modifications of glucarpidase by PEGylation or by genetic fusion to HSA is thus a promising strategy to 499 
allow these molecules to be used optimally in drug detoxification or in ADEPT.  500 
The data presented in Figs 2-6 and appendix A indicate that the production of pure and active PEG-CPG2 501 
and HSA-CPG2 was successfully achieved. The mass spectra analysis confirmed the formation of the 502 
HSA-CPG2, Appendix B. However, it was important to verify that the conjugated forms of CPG2 503 
retained enzyme activity – it remained possible that attachment of large additional molecules might 504 
sterically hinder access to the active site of CPG2. Surprisingly, enzyme activity studies indicate that 505 
HSA-CPG2 has slightly increased catalytic activity relative to free CPG2 – the Vmax of the former was 506 
48.72 ±4.389 µM/min whereas unconjugated CPG2 has a Vmax of 24.35 ±1.91 µM/min 
13
. In the case of 507 
PEGylated CPG2, the catalytic activity found to be slightly lower than that of unconjugated CPG2 (Vmax 508 
value of PEG-CPG2: 20.69 ±1.428 µM/min). Thus, the attached PEG may slightly restrict the access of 509 
the substrate to the enzyme active site or slightly alter the enzyme’s conformation. The results of far UV 510 
spectroscopy (CD) suggest that significant structural changes in secondary structure components of each 511 
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protein from induced by PEGylation and/or HSA conjugation compared with the CD scan and its deduced 512 
secondary structure results of free Xen-CPG2 recently published by our group 
13
. 513 
To compare the stability of the modified forms of CPG2 with the free enzyme, we incubated them with 514 
human blood serum for a total of 14 days. Fig 7 and fig 8 confirm that both HSA-CPG2 and PEG-CPG2 515 
are significantly more stable than free CPG2 and that they also have longer half-lives. In the latter case, 516 
PEGylation (incorporation of PEG negative charged molecules) is known to stabilize the conformation of 517 
proteins by increasing the intramolecular hydrogen bonding and increasing the hydrophilicity 
29, 30
. 518 
Increasing protein conformation also restricts access of proteases to the conjugated protein. On the other 519 
hand, HSA, which is well known to be non-immunogenic and biocompatible, also extends the half-life of 520 
the HSA-protein therapeutics 
31
.  521 
A PBMC proliferation assay, where T-cell (in the PBMCs) proliferation and differentiation is induced 522 
upon exposure to their cognate antigens, is considered to be a helpful tool during preclinical safety 523 
assessment and is used efficiently to evaluate and predict immunological effects of biopharmaceuticals 
32
. 524 
To assess the potential immunotoxicity of the modified CPG2s relative to the free CPG2, we, therefore, 525 
carried out an ex-vivo lymphocyte proliferation assay. Our results (Fig.9) indicated that in case of PEG-526 
CPG2 no significant induction of T-cell proliferation was observed, indicating that the attached PEG 527 
molecules are able to mask the immunogenic epitopes in CPG2 that react with immune cells and induce 528 
immunogenicity. In contrast, HSA-CPG2 triggered a significant increase in T-cell proliferation compared 529 
with the negative control. This unexpected result, which apparently contradicts the protein stability results 530 
(Figs 7 and 8), could be explained by the presence of endotoxin impurities, which might induce 531 
immunogenicity. We, however, carried out further purification steps to remove any remaining endotoxin 532 
but obtained the same results. Further study is needed to establish the cause of the observed 533 
immunogenicity. 534 
Collectively, our results show that conjugation of CPG2 with HSA or with PEG has a significant effect on 535 
CPG2 structural and functional stability in vitro and ex-vivo. Furthermore, PEGylated CPG2 was shown 536 
to have a reduced immunogenic effect on PBMCs compared with free CPG2. Our findings pave the way 537 
for in vivo studies and possible clinical investigation using modified forms of CPG2.   538 
Conclusion  539 
Glucarpidase (CPG2) is an important enzyme used in antibody directed enzyme prodrug therapy 540 
(ADEPT) for cancer treatment but with several pitfalls such as host immune response and proteases 541 
degradation. The Human serum albumin and PEG molecules are good half-life extenders with several 542 
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beneficial features, such as resistance to proteases degradation and low immune response. In this work we 543 
successfully carried out conjugation of HSA and PEG molecules to our newly isolated glucarpidase 544 
(CPG2), generating two novel glucarpidase conjugates, HSA-CPG2 and PEG-CPG2. We demonstrated 545 
that both HSA and PEG molecules could be conjugated to glucarpidase without compromising the critical 546 
property of the target protein such as enzyme activity. Our work shows that both glucarpidase conjugates 547 
have serum half-lives much higher than the free glucarpidase. We also show that PEG-CPG2 have a 548 
reduced immunogenic effect on PBMCs compared with free CPG2. Our work paves the way for the in 549 
vivo clinical investigation and clinical trials using our novel modified forms of CPG2 for cancer treatment 550 
and drug detoxification.   551 
 552 
Appendices 553 
Appendix A 554 
 555 











Appendix B.1: Mass spectra and matching peptide sequences for Carboxypeptidase G2 (matching 565 





Appendix B.2: Mass spectra and matching peptide sequences for human serum albumin (matching 569 
peptides are highlighted) 570 
 571 
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